Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking...

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Signal transducer and activator of transcription 3 (STAT3) is implicated in cancer development and is a key therapeutic target.
• Developing STAT3 inhibitors that spare the related STAT1 protein presents a significant challenge.
• The precise mechanisms underlying the selectivity of existing STAT3 inhibitors remain unclear.

Purpose of the Study:

• To elucidate the molecular mechanisms governing the selectivity of 13 tested STAT3 inhibitors.
• To investigate why these inhibitors target STAT3 while sparing STAT1.

Main Methods:

• Utilized extensive molecular dynamics simulations.
• Employed ensemble docking simulations to analyze inhibitor-protein interactions.
• Focused on the SH2 domain, DNA-binding, and coil-coil domains of STAT1 and STAT3.

Main Results:

• Inhibitors bind non-specifically to large protein surface areas rather than the SH2 dimerization interface.
• Binding to the SH2 domain is similar for both STAT1 and STAT3, failing to explain selectivity.
• A new mechanism, 'selectivity by distraction,' is proposed, where inhibitors preferentially bind to STAT1's DNA-binding and coil-coil domains, leaving STAT3's SH2 domain more accessible.

Conclusions:

• Existing STAT3 inhibitors do not achieve selectivity through preferential binding to the STAT3 SH2 domain.
• 'Selectivity by distraction' explains how inhibitors achieve higher effective concentrations at the STAT3 SH2 domain by weaker interactions with STAT1 domains.
• This finding offers a new perspective for designing more effective and selective STAT3-targeted anticancer therapies.